RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients

被引：3
|
作者：
Singh, Dave
Banner, Kathy
Newman, Kenneth
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Bronchodilators; COPD; -; management; Anti-inflammatory;
D O I：
10.1183/13993003.congress-2016.PA4052
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4052
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
    Venkatasamy, Radhakrishnan
    Page, Clive
    Spina, Domenico
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [32] A Phase I, Randomised, Double Blind, Placebo Controlled, Study To Assess The Safety, Tolerability And Pharmacokinetics Of Multiple Inhaled Doses Of Rpl554 Administered By Nebuliser To Healthy Male Subjects And Stable COPD Patients
    Singh, D.
    Abbott-Banner, K. H.
    Reid, F.
    Newman, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [33] Anti-inflammatory effects of PDE3/4 inhibitor ensifentrine in peripheral blood mononuclear cells from COPD patients
    Lea, Simon
    Li, Jian
    Littolf, Kieran
    Vijayacumaran, Kajaluckcika
    Singh, Dave
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [34] Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective
    Gan, Qiming
    Wu, Yanjuan
    Su, Xiaofen
    Wang, Jingcun
    Zhang, Haojie
    Zhang, Nuofu
    Wu, Kang
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (02) : 223 - 224
  • [35] Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
    Bjermer, Leif
    Abbott-Banner, Katharine
    Newman, Kenneth
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 58
  • [36] Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers
    Lucci, Germano
    Mariotti, Fabrizia
    Santoro, Debora
    Acerbi, Daniela
    Poli, Gianluigi
    Nandeuil, Marie-Anna
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [37] Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers
    Esposito, Oriana
    Mariotti, Fabrizia
    Acerbi, Daniela
    Compagnoni, Anna
    Nandeuil, Marie-Anna
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [38] THE DUAL PHOSPHODIESTERASE 3 AND 4 INHIBITOR, RPL554, ENHANCES FORSKOLIN-STIMULATED, CFTR-DEPENDENT CURRENTS IN CYSTIC FIBROSIS AIRWAY EPITHELIA
    Turner, M.
    Matthes, E.
    Abbott-Banner, K.
    Randell, S. H.
    Thomas, D. Y.
    Hanrahan, J. W.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 278 - 278
  • [39] ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION WHEN ADMINISTERED BY METERED DOSE INHALER IN PATIENTS WITH COPD
    Rheault, Tara
    Leaker, Brian
    Singh, Dave
    Bengtsson, Thomas
    Rickard, Kathleen
    CHEST, 2020, 158 (04) : 1762A - 1763A
  • [40] Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers
    Ferrari, Antonio
    Compagnoni, Anna
    Nandeuil, Anne
    Maison-Blanche, Pierre
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2016, 68 (01) : 41 - 48
12345